An Update on Molecular Diagnostics in Prostate Cancer
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (30 September 2025) | Viewed by 795
Special Issue Editors
Interests: kidney cancer; prostate cancer; kidney transplantation; metabolomics
Special Issues, Collections and Topics in MDPI journals
Interests: kidney cancer; prostate cancer; molecular markers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Prostate cancer, the most frequent tumor in men, is a heterogeneous disease with variable clinical outcomes. Although most patients affected by indolent tumors are essentially treated with surgery or radiotherapy, a subset of patients presents with aggressive disease or recurrence/progress after primary treatment. Recent advances in understanding prostate cancer pathogenesis, coupled with the introduction of high-throughput technologies, have led to the identification and validation of novel molecular biomarkers, representing a range of macromolecules assayed from different sample types, to help guide the clinical management of prostate cancer, including early detection, diagnosis, prognostication, and targeted therapeutic. This Special Issue of Diagnostics is dedicated to studies exploring the discovery and application of novel biomarkers and diagnostic technologies that could be used in the clinical management of this tumor.
Prof. Dr. Giuseppe Lucarelli
Dr. Francesco Lasorsa
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- imaging
- molecular biomarkers
- diagnosis
- prognosis
- risk stratification
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
